Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2025-03-05
Target enrollment:
Participant gender:
Summary
This study will compare the clinical activity of novel regimens (in combination or as single
agents) to standard of care in participants with relapsed/refractory advanced NSCLC. The
study will be conducted in two parts; Part 1 is an optional, non-randomized part based on
safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate
additional data to qualify novel regimens for the randomized study. Part 2 is a randomized,
Phase II study comparing the efficacy and safety of these novel regimens with SoC.